Literature DB >> 23917410

Optimization and production of pyrrolidone antimicrobial agent from marine sponge-associated Streptomyces sp. MAPS15.

G Sathiyanarayanan1, R Gandhimathi, B Sabarathnam, G Seghal Kiran, Joseph Selvin.   

Abstract

Twenty-nine actinobacterial strains were isolated from marine sponge Spongia officinalis and screened for antagonistic activity against various bacterial and fungal pathogens. The active antibiotic producer MAPS15 was identified as Streptomyces sp. using 16S rRNA phylogenetic analysis. The critical control factors were selected from Plackett-Burman (PB) factorial design and the bioprocess medium was optimized by central composite design (CCD) for the production of bioactive metabolite from Streptomyces sp. MAPS15. The maximum biomass and active compound production obtained with optimized medium was 6.13 g/L and 62.41 mg/L, respectively. The economical carbon source, paddy straw was applied for the enhanced production of bioactive compound. The purified active fraction was characterized and predicted as pyrrolidone derivative which showed broad spectrum of bioactivity towards indicator organisms. The predicted antimicrobial spectra suggested that the Streptomyces sp. MAPS15 can produce a suite of novel antimicrobial drugs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23917410     DOI: 10.1007/s00449-013-1023-2

Source DB:  PubMed          Journal:  Bioprocess Biosyst Eng        ISSN: 1615-7591            Impact factor:   3.210


  9 in total

1.  Antibacterial metabolites from the Actinomycete Streptomyces sp. P294.

Authors:  Huining Su; Hongwei Shao; Keqin Zhang; Guohong Li
Journal:  J Microbiol       Date:  2016-02-02       Impact factor: 3.422

2.  Druggability and Binding Site Interaction Studies of Potential Metabolites Isolated from Marine Sponge Aurora globostellata against Human Epidermal Growth Factor Receptor-2.

Authors:  M Sugappriya; D Sudarsanam; Raj Bhaskaran; Jerrine Joseph; Arumugam Suresh
Journal:  Bioinformation       Date:  2017-08-31

3.  Taxonomic characterization and antimicrobial compound production from Streptomyces chumphonensis BDK01 isolated from marine sediment.

Authors:  Madheslu Manikandan; Vasudevan Gowdaman; Kasiviswanathan Duraimurugan; Solai Ramatchandirane Prabagaran
Journal:  3 Biotech       Date:  2019-04-04       Impact factor: 2.406

Review 4.  Diversity and Biotechnological Potential of Marine Actinomycetes from India.

Authors:  Gargi Sarkar; K Suthindhiran
Journal:  Indian J Microbiol       Date:  2022-05-15

5.  Terpenoid bioactive compound from Streptomyces rochei (M32): taxonomy, fermentation and biological activities.

Authors:  Raasaiyah Pazhanimurugan; Manikkam Radhakrishnan; Thangavel Shanmugasundaram; Venugopal Gopikrishnan; Ramasamy Balagurunathan
Journal:  World J Microbiol Biotechnol       Date:  2016-08-25       Impact factor: 3.312

Review 6.  Bioprospecting Sponge-Associated Microbes for Antimicrobial Compounds.

Authors:  Anak Agung Gede Indraningrat; Hauke Smidt; Detmer Sipkema
Journal:  Mar Drugs       Date:  2016-05-02       Impact factor: 5.118

7.  Evaluation of Antimicrobial, Enzyme Inhibitory, Antioxidant and Cytotoxic Activities of Partially Purified Volatile Metabolites of Marine Streptomyces sp.S2A.

Authors:  Saket Siddharth; Ravishankar Rai Vittal
Journal:  Microorganisms       Date:  2018-07-18

8.  Genome Mining Coupled with OSMAC-Based Cultivation Reveal Differential Production of Surugamide A by the Marine Sponge Isolate Streptomyces sp. SM17 When Compared to Its Terrestrial Relative S. albidoflavus J1074.

Authors:  Eduardo L Almeida; Navdeep Kaur; Laurence K Jennings; Andres Felipe Carrillo Rincón; Stephen A Jackson; Olivier P Thomas; Alan D W Dobson
Journal:  Microorganisms       Date:  2019-09-26

9.  Discovery of novel small molecule modulators of Clavibacter michiganensis subsp. michiganensis.

Authors:  Xiulan Xu; Anand Kumar; Loïc Deblais; Ruby Pina-Mimbela; Corey Nislow; James R Fuchs; Sally A Miller; Gireesh Rajashekara
Journal:  Front Microbiol       Date:  2015-10-19       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.